Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Després JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nuñez-Cortes JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner Ž, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokgözoğlu LS, Tomlinson B, Tybjærg-Hansen A, Valensi P, Vrablík M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P. Fruchart JC, et al. Among authors: koenig w. Cardiovasc Diabetol. 2019 Jun 4;18(1):71. doi: 10.1186/s12933-019-0864-7. Cardiovasc Diabetol. 2019. PMID: 31164165 Free PMC article. Review.
C-reactive protein in the Heart Protection Study.
Ridker PM, Koenig W, Kastelein JJ. Ridker PM, et al. Among authors: koenig w. Lancet. 2011 Jun 4;377(9781):1918; author reply 1918-9. doi: 10.1016/S0140-6736(11)60807-6. Lancet. 2011. PMID: 21641475 No abstract available.
Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.
Zannad F, De Backer G, Graham I, Lorenz M, Mancia G, Morrow DA, Reiner Z, Koenig W, Dallongeville J, Macfadyen RJ, Ruilope LM, Wilhelmsen L; ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Zannad F, et al. Among authors: koenig w. Fundam Clin Pharmacol. 2012 Apr;26(2):163-74. doi: 10.1111/j.1472-8206.2011.01023.x. Epub 2012 Jan 5. Fundam Clin Pharmacol. 2012. PMID: 22220636 Review.
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
Ridker PM, Amarenco P, Brunell R, Glynn RJ, Jukema JW, Kastelein JJ, Koenig W, Nissen S, Revkin J, Santos RD, Schwartz PF, Yunis C, Tardif JC; Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators. Ridker PM, et al. Among authors: koenig w. Am Heart J. 2016 Aug;178:135-44. doi: 10.1016/j.ahj.2016.05.010. Epub 2016 May 28. Am Heart J. 2016. PMID: 27502861 Free article. Clinical Trial.
1,113 results